Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Zhongguo Fei Ai Za Zhi
2018 May 20;215:419-424. doi: 10.3779/j.issn.1009-3419.2018.05.11.
Show Gene links
Show Anatomy links
[Research Progress of KRAS Mutation in Non-small Cell Lung Cancer].
Liu L
,
Wei S
.
Abstract
Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for 80%-85% of all patients with lung cancer, the majority of patients with lung cancer at the time of diagnosis is in the advanced stage. The development of target therapy based on has changed the mode of treatment in patients with advanced NSCLC. In NSCLC, epidermal growth factor receptor mutation (EGFR) fusion with echinoderm microtubule-associated protein-like4-anaplastic lymphoma kinase (EML4-ALK) has been shown to be a powerful biomarker. It is well known that KRAS is also NSCLC one of the most common mutations in oncogenes, although more than 20 years ago KRAS mutation was found in NSCLC. At present, although there are many drugs used to treat NSCLC patients with KRAS mutation, there is no selective or specific inhibitor for the direct elimination of KRAS activity. NSCLC patients with KRAS mutation have poor responsiveness to most systemic therapy. However, individualized therapy for activated signaling pathways with targeted drugs has a good effect on the prognosis of NSCLC patients with KRAS mutation. In addition, the prognostic and predictive role of KRAS mutation in NSCLC remains unclear. In this review, we focus on the research progress of NSCLC with KRAS mutation, including molecular biology, clinicopathological features, prognosis and prediction of KRAS mutation, which will help to improve the understanding of NSCLC in KRAS mutation. .
Chen,
KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma.
2017, Pubmed
Chen,
KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma.
2017,
Pubmed
Davar,
Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma.
2015,
Pubmed
Davies,
AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models.
2007,
Pubmed
Del Re,
Implications of KRAS mutations in acquired resistance to treatment in NSCLC.
2018,
Pubmed
Dong,
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.
2017,
Pubmed
Ettinger,
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
2017,
Pubmed
Goldman,
Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy.
2016,
Pubmed
Györffy,
Biomarkers downstream of RAS: a search for robust transcriptional targets.
2010,
Pubmed
Ihle,
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
2012,
Pubmed
Jones,
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors.
2015,
Pubmed
Jänne,
Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer.
2015,
Pubmed
Jänne,
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
2017,
Pubmed
Lee,
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.
2018,
Pubmed
Li,
Synergistic effects of sorafenib in combination with gemcitabine or pemetrexed in lung cancer cell lines with K-ras mutations.
2016,
Pubmed
McCubrey,
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.
2007,
Pubmed
Mellema,
Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer.
2015,
Pubmed
Pao,
New driver mutations in non-small-cell lung cancer.
2011,
Pubmed
Park,
KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.
2017,
Pubmed
Renaud,
MicroRNAs: a new tool in the complex biology of KRAS mutated non-small cell lung cancer?
2017,
Pubmed
Schabath,
Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.
2016,
Pubmed
Scheel,
PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations.
2016,
Pubmed
Shepherd,
Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.
2013,
Pubmed
Tang,
Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer.
2016,
Pubmed
Tao,
Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
2016,
Pubmed
Tomasini,
Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.
2016,
Pubmed
Tomasini,
EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer.
2016,
Pubmed
Ulivi,
Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
2016,
Pubmed
,
Echinobase
Ying,
Should KRAS mutation still be used as a routine predictor of response to EGFR-TKIs in advanced non-small-cell lung cancer? A revaluation based on meta-analysis.
2015,
Pubmed
Yu,
Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas.
2015,
Pubmed
Zeng,
Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation.
2017,
Pubmed
Zer,
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
2016,
Pubmed
Zhao,
Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma.
2014,
Pubmed
